The British In Vitro Diagnostics Association (BIVDA) has released its new three-year strategy, entitled ‘Diagnostics for All’.
BIVDA says its ambition remains to represent the core interests of its members to shape a better healthcare system for patients: one which puts diagnostics at the heart of healthcare. It says it will work collaboratively, and with increased assertiveness, with stakeholders to deliver fundamental change.
BIVDA members will continue to enjoy the current high levels of service and support in all areas, with an additional focus on antimicrobial resistance, and infectious disease, near-patient testing and pathway innovation, and genomics in cancer, infection, and both rare and common diseases.
The strategy for 2024-27, sets out how BIVDA is seeking to make tangible progress in these areas and increase the value of medical diagnostics in the healthcare system.
In her introduction to the document, Helen Dent, BIVDA Chief Executive, writes: “BIVDA will focus on demonstrating the value of medical diagnostics across different settings and uses by patients, clinicians and the public. This will involve a different approach to traditional trade body activity as we pivot to being a partner, an enabler and facilitator to our network and utilise our unique position as an independent organisation with unrivalled access to knowledge, technology, ideas and expertise within our secretariat team and massive membership base.”
Read the full document by clicking here.
